-
In a leadership shakeup, the diet company says CEO Sima Sistani would leave her role effective immediately. Tara Comonte, a board member and former Shake Shack exec, was named interim chief.
-
New research shows that the number of 12- to 25-year-olds who used the GLP-1 medications climbed from about 8,700 a month in 2020 to 60,000 a month in 2023.
-
But some health experts worry about traditional diet companies and gyms getting in the medication business and believe the drugs will cater to society’s need for quick fixes.
-
The European Medicines Agency regulatory committee joins the FDA in saying there's no known tie between the semaglutide obesity drugs and suicide.
-
Health officials say a preliminary review finds no connection between suicidal thoughts and a new class of diabetes and obesity drugs, but they cannot definitively rule out “a small risk may exist."
-
Weight-loss medications tamp down hunger — often dramatically — causing some people to lose the pleasure of communing over food at a festive family meal.
-
Many welcome what they say is greater control over what they eat. “I don’t care about the bread as much. I still eat what I enjoy,” says one Tampa area woman who lost more than 200 pounds taking Mounjaro.
-
Wegovy is a high-dose version of the diabetes treatment Ozempic. The international trial showed the weekly injections prevented heart attacks, strokes and heart-related deaths.
-
The drugs can slow digestion so much that it puts patients at increased risk for pulmonary aspiration, which can cause dangerous lung damage, infections and even death, says one anesthesiologist.
-
Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.